Bank of America Corp DE Purchases Shares of 91,224 aTyr Pharma, Inc. (NASDAQ:ATYR)

Bank of America Corp DE bought a new stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 91,224 shares of the company's stock, valued at approximately $330,000. Bank of America Corp DE owned 0.11% of aTyr Pharma as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. D.A. Davidson & CO. acquired a new position in aTyr Pharma in the fourth quarter valued at about $141,000. Charles Schwab Investment Management Inc. bought a new position in aTyr Pharma in the 4th quarter valued at about $144,000. Victory Capital Management Inc. acquired a new position in shares of aTyr Pharma in the 4th quarter valued at approximately $37,000. Raymond James Financial Inc. bought a new stake in shares of aTyr Pharma during the 4th quarter worth approximately $39,000. Finally, Farther Finance Advisors LLC acquired a new stake in shares of aTyr Pharma during the 4th quarter worth approximately $88,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ATYR shares. Leerink Partners assumed coverage on shares of aTyr Pharma in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a research note on Wednesday, June 4th. Finally, Leerink Partnrs upgraded aTyr Pharma to a "strong-buy" rating in a research report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $18.60.

aTyr Pharma Price Performance

Shares of NASDAQ:ATYR traded down $0.34 during trading on Tuesday, hitting $5.14. 2,832,472 shares of the company were exchanged, compared to its average volume of 1,061,265. aTyr Pharma, Inc. has a 1-year low of $1.42 and a 1-year high of $5.98. The company has a market capitalization of $457.46 million, a P/E ratio of -6.35 and a beta of 0.88. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. The business's 50 day moving average is $3.85 and its 200-day moving average is $3.62.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. Equities analysts forecast that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.